It appears that Mesoblast has also completed the submission of its rolling BLA to the FDA for approval of its product candidate for acute gvhd.
From today's anouncement:
About MesoblastSee below for comparison:
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a world leader in developing allogeneic (off-the- shelf) cellular medicines. The Company has leveraged its proprietary cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Two products have been commercialized in Japan and Europe by its licensees, and it has established commercial partnerships in Europe and China for certain Phase 3 assets. In the United States, Mesoblast completed submission of a rolling Biologics License Application to the FDA to seek approval of its product candidate for acute graft versus host disease following a successful Phase 3 trial and is completing Phase 3 trials for its advanced heart failure and chronic low back pain product candidates.
From previous announcement dated 27/11/2019 (Mesoblast Chairman Message to 2019 AGM)
About Mesoblast
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a world leader in developing allogeneic (off-theshelf) cellular medicines. The Company has leveraged its proprietary cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Two products have been commercialized in Japan and Europe by its licensees, and it has established commercial partnerships in Europe and China for certain Phase 3 assets. In the United States, Mesoblast has initiated submission of a rolling Biologics License Application to the FDA to seek approval of its product candidate for acute graft versus host disease following a successful Phase 3 trial, and is completing Phase 3 trials for its advanced heart failure and chronic low back pain product candidates. Mesoblast’s proprietary manufacturing process yields industrial-scale, frozen, off-the
You can verify the abvove info yourself by reading these two announcements.
- Forums
- ASX - By Stock
- MSB
- Submission of rolling BLA to the FDA for acute GVHD completed
Submission of rolling BLA to the FDA for acute GVHD completed
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
97.0¢ |
Change
0.030(3.19%) |
Mkt cap ! $1.107B |
Open | High | Low | Value | Volume |
94.0¢ | 98.0¢ | 92.0¢ | $3.342M | 3.477M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 33313 | 97.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
97.5¢ | 73982 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 33313 | 0.970 |
3 | 99109 | 0.965 |
5 | 168086 | 0.960 |
2 | 40000 | 0.955 |
6 | 72924 | 0.950 |
Price($) | Vol. | No. |
---|---|---|
0.975 | 73982 | 2 |
0.980 | 50627 | 6 |
0.985 | 34746 | 2 |
0.990 | 69957 | 4 |
0.995 | 59746 | 2 |
Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
TON
TRITON MINERALS LTD
Adrian Costello, Executive Director
Adrian Costello
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online